N-cadherin: A novel target for cancer therapy?

Drugs of the Future

Volumn 32, Issue 10, 2007, Pages 925-930

  Kelland, Lloyd ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADH 1; CAPECITABINE; CARBOPLATIN; DOCETAXEL; FIBROBLAST GROWTH FACTOR; GELATINASE B; MELPHALAN; N ACETYLCYSTEINYLHISTIDYLALANYLVALYLCYSTEINAMIDE; NERVE CELL ADHESION MOLECULE; PACLITAXEL; PENTAPEPTIDE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER THERAPY; CELL MIGRATION; CLINICAL TRIAL; COLON TUMOR; CONSTIPATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; HUMAN; MELANOMA; METASTASIS; MONOTHERAPY; NONHUMAN; OVARY CARCINOMA; PAIN; PANCREAS CANCER; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION; VOMITING;

EID: 36749027080     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.10.1123776     Document Type: Review

References (38)

1. Hanahan, D., Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100(1): 57-70.
2. Derycke, L.D.M., Bracke, M.E. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 2004, 48(5-6): 463-76.
3. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2(6): 442-54.
4. Hazan, R.B., Qiao, R., Keren, R., Badano, I., Suyama, K. Cadherin switching in tumor progression. Ann NY Acad Sci 2004, 1014: 155-63.
5. Maeda, M., Johnson, K.R., Wheelock, M.J. Cadherin switching: Essential for behavioural but not morphological changes during an epithelium to mesenchyme transition. J Cell Sci 2005, 118(Pt. 5): 873-87.
6. Umbas, R., Isaacs, W.B., Bringuier, P.P. et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994, 54(14): 3929-33.
7. Tomita, K., van Bokhoven, A., van Leenders, G.J.L.H. et al. Cadherin switching in human prostate cancer progression. Cancer Res 2000, 60(13): 3650-4.
8. Nakajima, S., Doi, R., Toyoda, E. et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 2004, 10 (12, Pt. 1): 4125-33.
9. Rosivatz, E., Becker, I., Bamba, M. et al. Neoexpression of N-cadherin in E-cadherin positive colon cancers. Int J Cancer 2004, 111(5): 711-9.
10. Nagi, C., Guttman, M., Jaffer, S. et al. N-cadherin expression in breast cancer: Correlation with an aggressive histologic variant-invasive micropapillary carcinoma. Breast Cancer Res Treat 2005, 94(3): 225-35.
11. Lascombe, I., Clairotte, A., Fauconnet, S. et al. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res 2006, 12(9): 2780-7.
12. Islam, S., Carey, T.E., Wolf, G.T., Wheelock, M.J., Johnson, K.R. Expression of N-cadherin by human squamous carcinoma cells induces a scattered fibroblastic phenotype with disrupted cell-cell adhesion. J Cell Biol 1996, 135(6, Pt. 1): 1643-54.
13. Nieman, M.T., Prudoff, R.S., Johnson, K.R., Wheelock, M.J. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 1999, 147(3): 631-44.
14. Hazan, R.B., Phillips, G.R., Qiao, R.F., Norton, L., Aaronson, S.A. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion and metastasis. J Cell Biol 2000, 148(4): 779-90.
15. Suyama, K., Shapiro, I., Guttman, M., Hazan, R.B. A signalling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002, 2(4): 301-14.
16. Hulit, J., Suyama, K., Chung, S. et al. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res 2007, 67(7): 3106-16.
17. Li, G., Satamoorthy, K., Herlyn, M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001, 61(9): 3819-25.
18. Makagiansar, I.T., Yusuf-Makagiansar, H., Ikesue, A., Calcagno, A.M., Murray, J.S., Siahaan, T.J. N-cadherin involvement in the heterotypic adherence of malignant T-cells to epithelia. Mol Cell Biochem 2002, 233(1-2): 1-8.
19. Tran, N.L., Adams, D.G., Vaillancourt, R.R., Heimark, R.L. Signal transduction from N-cadherin increases Bcl-2. J Biol Chem 2002, 277(36): 32905-14.
20. Zhang, B., Groffen, J., Heisterkamp, N. Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. Leukemia 2007, 21(6): 1189-97.
21. Yang, J., Mani, S.A., Donaher, J.L. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117(7): 927-39.
22. Yang, J., Mani, S.A., Weinberg, R.A. Exploring a new twist on tumor metastasis. Cancer Res 2006, 66(9): 4549-52.
23. Alexander, N.R., Tran, N.L., Rekapally, H., Summers, C.E., Glackin, C., Heimark, R.L. N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. Cancer Res 2006, 66(7): 3365-9.
24. Yang, Z., Zhang, X., Gang, H. et al. Up-regulation of gastric cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun 2007, 358(3): 925-30.
25. Shintani, Y., Hollingsworth, M.A., Wheelock, M.J., Johnson, K.R. Collagen 1 promotes metastasis in pancreatic cancer by activating c-Jun NH2-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res 2006, 66(24): 11745-53.
26. Jiang, C., Pecha, J., Hoshino, I., Ankrapp, D., Xiao, H. TIP30 mutant derived from hepatocellular carcinoma specimens promotes growth of HepG2 cells through up-regulation of N-cadherin. Cancer Res 2007, 67(8): 3574-82.
27. Blaschuk, O.W., Rowlands, T.M. Cadherins as modulators of angiogenesis and the structural integrity of blood vessels. Cancer Metast Rev 2000, 19: 1-5.
28. Cavallaro, U., Liebner, S., Dejana, E. Endothelial Cadherins and tumor angiogenesis. Exp Cell Res 2006, 312(5): 659-67.
29. Luo, Y., Radice, G.L. N-cadherin acts upstream of VE-cadherin in controlling vascular morphogenesis. J Cell Biol 2005, 169(1): 29-34.
30. Blaschuk, O.W., Sullivan, R., David, S., Pouliot, Y. Identification of a Cadherin cell adhesion recognition sequence. Dev Biol 1990, 139(1): 227-9.
31. Doherty, P., Rowlett, L.H., Moore, S.E., Mann, D.A., Walsh, F.S. Neurite outgrowth in response to transfected N-CAM and N-cadherin reveals fundamental differences in neuronal responsiveness to CAMs. Neuron 1991, 6(2): 247-58.
32. Williams, E., Williams, G., Gour, B.J., Blaschuk, O.W., Doherty, P. A novel family of cyclic peptide antagonists suggests that N-cadherin specificity is determined by amino acids that flank the HAV motif. J Biol Chem 2000, 275(6): 4007-12.
33. Erez, N., Zamir, E., Gour, B.J., Blaschuk, O.W., Geiger, B. Induction of apoptosis in cultured endothelial cells by a cadherin antagonist peptide: Involvement of fibroblast growth factor receptor mediated signalling. Exp Cell Res 2004, 294(2): 366-78.
34. Li, H., Price, D.K., Figg, W.D. ADH-1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anti-cancer Drugs 2007, 18(5): 563-8.
35. Kelland, L. ADH-1: An N-cadherin antagonist targeting cancer vascularization. Curr Opin Mol Ther 2007, 9(1): 86-91.
36. Gupta, M., Barnes, D., Losos, J., Spehar, G., Bednarcik, M., Peters, W.P. Synergistic anti-tumor activity of ADH-1 in vitro and in vivo in combination with paclitaxel in ovarian cancer cell lines. Proc Amer Assoc Cancer Res (AACR) 2007, 48: Abst LB-356.
37. Shintani, Y., Johnson, K.R., Wheelock, M.J. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Proc Amer Assoc Cancer Res (AACR) 2007, 48: Abst LB-261.
38. Chu, Q., Jonker, D.J., Knox, J. et al. An open label safety and efficacy phase 2a study of the N-cadherin (N-cad) antagonist ADH-1 in subjects with N-cadherin expressing solid tumors. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 3567.